Great news! Scanning global news re any update for the recent CD24-Exosome C19 (ARDS) study originally carried out of Israel and lastly Greece which, if positive, may have a significant impact in harnessing confidence towards the effectiveness of exosomes as a category in this particular indication. I believe Exopharm previously indicated they have been in touch with the israeli company. Be also nice to get additional updates on the Red Cross blood bank collaboration - is that still on? or not... regardless, US collaboration now with the patent in hand became much more likely and near.
